Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2007 2
2008 2
2010 2
2015 1
2016 2
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF, Schwöppe C, Brand C, Harrach S, Brömmel K, Hintelmann H, Lenz G, Liersch R, Heinzow H, Schliemann C, Mesters RM, Berdel WE, Kessler T. Berdel AF, et al. Among authors: hintelmann h. Cancers (Basel). 2021 Jun 7;13(11):2841. doi: 10.3390/cancers13112841. Cancers (Basel). 2021. PMID: 34200318 Free PMC article. Review.
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Altvater B, Kailayangiri S, Spurny C, Flügge M, Meltzer J, Greune L, Urban K, Schwöppe C, Brand C, Schliemann C, Hintelmann H, Harrach S, Hartmann W, Abken H, Kuehle J, Schambach A, Görlich D, Berdel WE, Rossig C. Altvater B, et al. Among authors: hintelmann h. Cancer Gene Ther. 2023 Oct;30(10):1355-1368. doi: 10.1038/s41417-023-00642-x. Epub 2023 Jun 30. Cancer Gene Ther. 2023. PMID: 37391502 Free PMC article.
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Brand C, Greve B, Bölling T, Eich HT, Willich N, Harrach S, Hintelmann H, Lenz G, Mesters RM, Kessler T, Schliemann C, Berdel WE, Schwöppe C. Brand C, et al. Among authors: hintelmann h. PLoS One. 2020 Feb 21;15(2):e0229271. doi: 10.1371/journal.pone.0229271. eCollection 2020. PLoS One. 2020. PMID: 32084238 Free PMC article.
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Berdel WE, Harrach S, Brand C, Brömmel K, Berdel AF, Hintelmann H, Schliemann C, Schwöppe C. Berdel WE, et al. Among authors: hintelmann h. Cancers (Basel). 2020 Nov 26;12(12):3536. doi: 10.3390/cancers12123536. Cancers (Basel). 2020. PMID: 33256235 Free PMC article.
Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T, Schwöppe C, Liersch R, Schliemann C, Hintelmann H, Bieker R, Berdel WE, Mesters RM. Kessler T, et al. Among authors: hintelmann h. Curr Drug Discov Technol. 2008 Mar;5(1):1-8. doi: 10.2174/157016308783769487. Curr Drug Discov Technol. 2008. PMID: 18537561
Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel W, Mesters RM, Berdel WE. Schwöppe C, et al. Among authors: hintelmann h. Thromb Res. 2010 Apr;125 Suppl 2:S143-50. doi: 10.1016/S0049-3848(10)70033-5. Thromb Res. 2010. PMID: 20433995
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE. Stucke-Ring J, et al. Among authors: hintelmann h. Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559. Oncotarget. 2016. PMID: 27738341 Free PMC article.
14 results